The use and efficacy of angiotensin-converting enzyme inhibitors for treatment of hypertension in young children following paediatric cardiac surgery: a case control comparison
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Angiotensin-converting enzyme inhibitor (ACE inhibitor) therapy in children after heart surgery can decrease mean arterial pressure. High and medium doses of ACE inhibitors were more effective in lowering blood pressure compared to low doses.
Area Of Science
- Cardiology
- Pediatric Cardiac Surgery
- Pharmacology
Background
- Limited data exists on the optimal use of angiotensin-converting enzyme inhibitors (ACE inhibitors) in pediatric patients post-cardiac surgery.
- Understanding titration, dosing, and efficacy is crucial for improving patient outcomes.
Purpose Of The Study
- To investigate the titration, optimal dosing, and efficacy of ACE inhibitors in pediatric patients following cardiac surgery.
- To compare the effects of ACE inhibitors on mean arterial pressure (MAP) in these patients.
Main Methods
- Retrospective single-centre study of 286 pediatric patients (ventricular septal defect or coarctation of the aorta repair) from 2017-2019.
- Medical records were reviewed for patient characteristics, outcomes, MAP response, and ACE inhibitor dosage.
- Comparison between patients receiving ACE inhibitors and a control group not receiving them postoperatively.
Main Results
- 59% of patients received ACE inhibitors postoperatively, with captopril and lisinopril being common.
- Patients on ACE inhibitors had higher baseline and early postoperative MAP compared to controls.
- High and medium doses of ACE inhibitors significantly decreased MAP over time, unlike low doses.
Conclusions
- Higher doses of angiotensin-converting enzyme inhibitors (ACE inhibitors) demonstrate a greater impact on reducing mean arterial pressure in pediatric cardiac surgery patients.
- These findings suggest dose-dependent efficacy of ACE inhibitors in managing blood pressure post-cardiac surgery.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...